EE820 Cost-Utility Analysis of an All-Preterm Infant Immunization With Nirsevimab Against Respiratory Syncytial Virus (RSV): Associated Disease at the Brazilian Private Healthcare System
Abstract
Authors
SF Watanabe J Santoro A Tolardo M Safadi RT Stein M Falavigna NB Schneider B Marmett S Soudani